Inclusion Criteria:
Subject is 18 years of age or older at the time of consent.
- Subject reports a quality-of-life rating of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS).
- Subject has primary focal axillary hyperhidrosis evidenced by at least 6 months of visible, detectable, focal, exaggerated sweating without any apparent explanation and at least two of the following:
- Bilateral and relatively symmetric
- Impairs daily activities
- Frequency of at least one episode per week
- Age of onset less than 25 years old
- Positive family history
- Cessation of focal sweating during sleep
- Subject is willing and able to comply with protocol requirements and all study visits
- Willing to have de-identified images of the treated areas taken for possible use in publications and presentations.
- Subject understands the study and has provided written informed consent
Exclusion Criteria:
Subject has secondary hyperhidrosis due to medications, infections, malignancy or endocrinopathy.
- Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization.
- Severe concurrent conditions such as cardiac disorders epilepsy, uncontrolled hypertension, and liver or kidney diseases.
- Any active skin condition in the treatment area, such as sores, psoriasis, eczema and rash.
- Swollen axillary lymph nodes.
- History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
- Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
- History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
- Prior endoscopic thoracic sympathectomy, liposuction or other surgery for hyperhidrosis in the treated area. Injection of botulinum toxin in the treated area within one year
- Use of Isotretinoin (Accutane®) within 6 months prior to study
- Oral anticholinergic medication use (e.g., Robinul) or cholinomimetic medication use within the last 4 weeks or planned use during the study's follow up phase.
- Currently participating in or recently participated in another clinical trial (within the last 30 days).
- History of or current neurologic deficit in the treatment limb.
- Known resistance to or history of difficulty with local anesthesia (lidocaine with epinephrine).
- Current or history of cancer, including skin cancer, or premalignant moles.
- Injury in the treatment area or any other condition that, in the opinion of the investigator, might make treatment unsafe.
- Subject has a pacemaker, defibrillator or other electronic implant anywhere in the body.
- Permanent implant in the treated area such as metal plates, screws and metal piercing or silicon.
- Females who are pregnant or nursing
- Female subjects of childbearing potential not willing to use an acceptable form of contraception for the duration of the study.